Skip to main content
Fig. 1 | BMC Pulmonary Medicine

Fig. 1

From: Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials

Fig. 1

Change from baseline in trough FEV1 at Week 12 (Efficacy population). Efficacy population consists of data from studies HZA106827, HZA106829, and HZA106837. Number of patients analyzed in a) Overall population: N = 193 placebo, N = 1,201 FF/VI 100/25 μg OD, N = 187 FF/VI 200/25 μg OD, N = 1,203 FF 100 μg OD, N = 186 FF 200 μg OD, N = 190 FP 500 μg BD; b) Japan cohort: N = 18 placebo, N = 46 FF/VI 100/25 μg OD, N = 13 FF/VI 200/25 μg OD, N = 46 FF 100 μg OD, N = 11 FF 200 μg OD, N = 10 FP 500 μg BD; c) Not-Japan cohort: N = 175 placebo, N = 1,155 FF/VI 100/25 μg OD, N = 174 FF/VI 200/25 μg OD, N = 1,157 FF 100 μg OD, N = 175 FF 200 μg OD, N = 180 FP 500 μg BD. The limits of the box represent the interquartile range (IQR) from the 25th to 75th percentiles, respectively, for the lower and upper limits of the box; error bars represent the minimum and maximum values within 1.5 × IQR below and above the 25th and 75th percentiles, respectively; the horizontal line within the box represents the median; + represents the mean; symbols represent data that are either <1.5 × IQR below the 25th percentile or >1.5 × IQR above the 75th percentile. BD twice daily, FEV 1 forced expiratory volume in one second, FF fluticasone furoate, FP fluticasone propionate, OD once daily, VI vilanterol

Back to article page